Immune Modulator Pidotimod Decreases the In Vitro Expression of CD30 in Peripheral Blood Mononuclear Cells of Atopic Asthmatic and Normal Children

Dimitrios Gourgiotis Research Laboratories, 2nd Department of Paediatrics, University of Athens, School of Medicine, “P & A Kyriakou” Children's Hospital, Levadias 13, Goudi, Athens, 11527, Greece

Nikolaos G. Papadopoulos Research Laboratories, 2nd Department of Paediatrics, University of Athens, School of Medicine, “P & A Kyriakou” Children's Hospital, Levadias 13, Goudi, Athens, 11527, Greece

Apostolos Bossios Research Laboratories, 2nd Department of Paediatrics, University of Athens, School of Medicine, “P & A Kyriakou” Children's Hospital, Levadias 13, Goudi, Athens, 11527, Greece

Petros Zamanis Research Laboratories, 2nd Department of Paediatrics, University of Athens, School of Medicine, “P & A Kyriakou” Children's Hospital, Levadias 13, Goudi, Athens, 11527, Greece

Photini Saxoni‐Papageorgiou Research Laboratories, 2nd Department of Paediatrics, University of Athens, School of Medicine, “P & A Kyriakou” Children's Hospital, Levadias 13, Goudi, Athens, 11527, Greece

Abstract

Recurrent viral infections are frequently observed in children with atopic asthma. In this study we investigated the ability of the synthetic immunomodulator pidotimod to affect in vitro the phenotype and/or cytokine profile of blood cells in relation to atopic asthma. Peripheral blood mononuclear cells were isolated from 13 atopic asthmatic and 9 normal children and stimulated in culture with mitogen either in the presence or not of the drug. Expression of surface markers was evaluated by flow cytometry, and production of interleukin‐4 and interferon‐gamma was measured in supernatants. Pidotimod was able to down‐regulate the expression of CD30 on cells from both atopic and normal subjects. Because CD30 has been associated with Th‐2 cells, this observation supports the possibility of pidotimod being able to affect the Th‐1/Th‐2 balance in atopic asthma.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Immune Modulator Pidotimod Decreases the In Vitro Expression of CD30 in Peripheral Blood Mononuclear Cells of Atopic Asthmatic and Normal Children

Information for

Open access

Opportunities

Help and information

Immune Modulator Pidotimod Decreases the In Vitro Expression of CD30 in Peripheral Blood Mononuclear Cells of Atopic Asthmatic and Normal Children

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature